Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+25
- Incentives
- Insufficient
- Confidence40
Anthropic is putting $100 million into a residency meant to train and credential 10,000 enterprise engineers on Claude by the end of 2027. Residents finish by running live Claude projects at their own employers, so the money buys deployments along with the teaching.
Perspective Coverage
7 publishers
- Builder
- Builder 29%
- Operator
- Operator 44%
- Investor
- Investor 27%
Reality
- Evidence62
- Adoption28
- Hype gap+18
- Incentives78
- Confidence60
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+10
- Incentives65
- Confidence50
Novartis says it saw evidence of clinical activity in secondary and exploratory analyses it has not disclosed, while the drug missed its primary endpoint, an expert-rated video timing of hand opening. Shares fell 11% in Zurich.
Reality
- Evidence62
- Adoption
- Insufficient
- Hype gap+35
- Incentives60
- Confidence60
Cellular Intelligence has added Bob Langer and Yann LeCun to its scientific advisory board. The $62m to $70m it has raised now has to take STEM-PD, the cell therapy Novo Nordisk dropped, through Phase 2.
Reality
- Evidence45
- Adoption15
- Hype gap+40
- Incentives65
- Confidence55
Prescribing has outrun the approval label for US children aged 8 to 11 with obesity. The trial behind the benefit claim followed them for 68 weeks. Those 68 weeks are the entire developmental record so far.
Reality
- Evidence50
- Adoption72
- Hype gap+14
- Incentives62
- Confidence55
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
- Evidence64
- Adoption34
- Hype gap+24
- Incentives80
- Confidence67
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
- Evidence45
- Adoption55
- Hype gap+20
- Incentives65
- Confidence45
The company's head of life sciences told Reuters that real lab work is still the final test in biology. Anthropic has not said which experiments the lab is running, and it has yet to run a clinical trial.
Perspective Coverage
5 publishers
- Builder
- Builder 28%
- Operator
- Operator 35%
- Investor
- Investor 37%
Reality
- Evidence55
- Adoption40
- Hype gap+30
- Incentives70
- Confidence57
Anthropic's June decision to keep Fable usage logs for 30 days has turned zero data retention into a procurement gate at Nvidia, Booz Allen and Palantir. The metadata channel stays open under the clause they are demanding.
Perspective Coverage
4 publishers
- Builder
- Builder 26%
- Operator
- Operator 35%
- Investor
- Investor 39%
Reality
- Evidence58
- Adoption62
- Hype gap+18
- Incentives74
- Confidence55
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Reality
- Evidence48
- Adoption52
- Hype gap+15
- Incentives62
- Confidence45
The device maker told regulators that an August 25 intrusion halted order processing and manufacturing, and the next company figure on the year comes with third-quarter results on October 28, 64 days after the incident was identified.
Reality
- Evidence60
- Adoption62
- Hype gap+12
- Incentives72
- Confidence63
The Federal Reserve says reaching customers is the top operational problem for small employers. One owner's account suggests part of that problem is detection, and the proximity that catches such signals is the first thing growth takes away.
Reality
- Evidence34
- Adoption
- Insufficient
- Hype gap+18
- Incentives55
- Confidence44
Money leaving GLP-1 names for hair-loss biotech is a bet that aesthetic, cash-pay indications carry drug margins without payer risk. The multiples on Veradermics, Absci and Cosmo already assume the approvals.
Reality
- Evidence34
- Adoption7
- Hype gap+58
- Incentives79
- Confidence45
McMaster researchers report that the appetite hormone cut liver inflammation and fibrosis in MASH mice regardless of food intake, body weight or liver fat. All of it is preclinical.
Reality
- Evidence42
- Adoption
- Insufficient
- Hype gap+30
- Incentives68
- Confidence40
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
- Evidence56
- Adoption74
- Hype gap+14
- Incentives66
- Confidence54
The runners-up behind Lilly and Novo are consolidating around a few late-stage assets. Readouts starting next year, not messaging, will decide who takes share.
Reality
- Evidence32
- Adoption24
- Hype gap+22
- Incentives66
- Confidence36